Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity

Radiotherapy (RT) has been used to control tumors by physically damaging DNA and inducing apoptosis; it also promotes antitumor immune responses via neoantigens release and augmenting immune-oncology agents to elicit systemic response. Tumor regression after RT can recruit inflammatory cells, such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Younes, Ahmed I., Barsoumian, Hampartsoum B., Sezen, Duygu, Verma, Vivek, Patel, Roshal, Wasley, Mark, Hu, Yun, Dunn, Joe D., He, Kewen, Chen, Dawei, Menon, Hari, Masrorpour, Fatemeh, Gu, Meidi, Yang, Liangpeng, Puebla-Osorio, Nahum, Cortez, Maria Angelica, Welsh, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750418/
https://www.ncbi.nlm.nih.gov/pubmed/33340886
http://dx.doi.org/10.1016/j.tranon.2020.100983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750418/
https://www.ncbi.nlm.nih.gov/pubmed/33340886
http://dx.doi.org/10.1016/j.tranon.2020.100983

Ejemplares similares